May 13th 2024
At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.
Study Indicates When Geographic Atrophy Will Reach Fovea
November 3rd 2023Without treatment, lesions > 500 µm away from the fovea will take anywhere from 3.07 years to 12.9 years to reach it. With pegcetacoplan treatment, the lesion will reach the fovea anywhere between 3.56 years – 15 years for monthly treatment and 3.47-14.6 years for treatment every other month.
Apellis Shares Update on Pegcetacoplan Injection Kits, Retinal Vasculitis Events
August 23rd 2023Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.
Retina Specialists Examine Avacincaptad Pegol for Geographic Atrophy
August 8th 2023Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.
Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision Loss
April 24th 2023In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.